| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/22/2005 | CA2487107A1 Novel targets for obesity from skeletal muscle |
| 06/21/2005 | US6909032 DNA encoding a macadamia integrifolia anti-microbial protein, constructs comprising the same and plant material comprising the constructs |
| 06/21/2005 | US6909031 Expression vector coding protein for use in the treatment of diabetes |
| 06/21/2005 | US6909000 Inhibiting particularly the activity of hepatitis C virus NS3-NS4A protease; peptidomimetics having a bridged bicyclic moiety at the P2 position. |
| 06/21/2005 | US6908993 Comprises nucleotide sequences coding membrane protein for use in treatment of tumors and cell proliferative diseases; antiinflammatory agents |
| 06/21/2005 | US6908988 Animal models; medical diagnosis; antitumor agents |
| 06/21/2005 | US6908987 Comprises nucleotide sequences coding peroxisome proliferator activator receptor protein (PCG) for modulating thermogenesis in adipocytes and treating obesity |
| 06/21/2005 | US6908984 Megakaryocytic protein tyrosine kinase I |
| 06/21/2005 | US6908919 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| 06/21/2005 | US6908918 Ketone spirocyclopropaneindene compounds; antineoplastic agents to inhibit tumor cell growth in vitro or in vivo; particularly effective against solid tumors and multi-drug resistant tumors |
| 06/21/2005 | US6908907 Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients |
| 06/21/2005 | US6908902 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 06/21/2005 | US6908901 Hepatitis C inhibitor peptide analogs |
| 06/21/2005 | US6908900 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 06/21/2005 | US6908899 Pro-inflammatory fibrinopeptide |
| 06/21/2005 | US6908898 Angiogenesis related molecules |
| 06/21/2005 | US6908897 At least one is a human or animal insulin analogue; coupled together with a diacid such as by reacting with suberic acid, bis(N-hydroxysuccinimidyl) ester |
| 06/21/2005 | US6908765 Polypeptide—human SR splicing factor 52 and a polynucleotide encoding the same |
| 06/21/2005 | US6908763 Mammalian common lymphoid progenitor cell |
| 06/21/2005 | US6908750 Gene encoding HM1.24 antigen protein and promoter thereof |
| 06/21/2005 | US6908748 The protein encoded by novel gene has two WW domains that participate in protein interactions in the N-terminal domain, and this protein binds to other proteins, thus regulates the intracellular signal transduction, gene expression |
| 06/21/2005 | US6908747 Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
| 06/21/2005 | US6908741 Receptor for advanced glycated endproducts (RAGE); solid phase synthesis; immunoassay |
| 06/21/2005 | US6908734 Sulfated CCR5 peptides for HIV-1 infection |
| 06/21/2005 | US6908623 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 06/21/2005 | US6908612 Virus coat protein/receptor chimeras and methods of use |
| 06/21/2005 | US6908611 Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| 06/21/2005 | US6908610 Stable granulocyte colony stimulating factor formulation containing one or more of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; one or more hydrophobic amino acids; and methionine |
| 06/21/2005 | CA2304926C Robo: a family of polypeptides and nucleic acids involved in nerve guidance |
| 06/21/2005 | CA2182303C Method of preparing a viral vector by homologous intermolecular recombination |
| 06/21/2005 | CA2145749C Thrombin activatable plasminogen derivatives |
| 06/21/2005 | CA2118498C A novel anti-neoplastic cytokine |
| 06/16/2005 | WO2005054870A2 METHODS FOR ASSESSING p19-Arf INTERACTIONS WITH cMyc |
| 06/16/2005 | WO2005054862A1 Screening assay and treatment |
| 06/16/2005 | WO2005054509A2 Assay and treatment |
| 06/16/2005 | WO2005054486A1 Method of preparing gene transfer reagent |
| 06/16/2005 | WO2005054440A2 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan |
| 06/16/2005 | WO2005054430A2 Hepatitis c virus inhibitors |
| 06/16/2005 | WO2005054426A2 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof |
| 06/16/2005 | WO2005054292A1 Compositions and methods related to a dimeric mhc class i and ii-like molecule (dsmhc i and dsmhc ii) |
| 06/16/2005 | WO2005054291A1 Single-chain insulin |
| 06/16/2005 | WO2005054290A2 Peptide hormones zalpha48 and zsig97 |
| 06/16/2005 | WO2005054286A2 Interleukin-11 fusion proteins |
| 06/16/2005 | WO2005054285A1 Gag binding proteins |
| 06/16/2005 | WO2005054284A2 Regulation involving abin-2 |
| 06/16/2005 | WO2005054274A1 Nanofiltration of dipeptides |
| 06/16/2005 | WO2005054236A1 Substituted quinolines for the treatment of cancer |
| 06/16/2005 | WO2005054187A1 Methods of preparing compounds useful as protease inhibitors |
| 06/16/2005 | WO2005053795A2 Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| 06/16/2005 | WO2005053751A1 Animal model for experimental allergic neuritis and uses thereof |
| 06/16/2005 | WO2005053745A1 Erythropoietin solution formulation |
| 06/16/2005 | WO2005053744A1 TREATMENT OF RHEUMATOID ARTHRITIS WITH HYPOXIA-INDUCIBLE FACTOR 1α ANTAGONISTS |
| 06/16/2005 | WO2005053741A1 Medicine containing genetically modified antibody against chemokine receptor ccr4 |
| 06/16/2005 | WO2005053740A1 Immune enhancer and enhanced antigen obtained therewith |
| 06/16/2005 | WO2005053738A1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
| 06/16/2005 | WO2005053736A1 Oral vaccine, method for its preparation and use thereof |
| 06/16/2005 | WO2005053735A1 Method of removing transition metals, especially from metathesis reaction products |
| 06/16/2005 | WO2005053734A1 Use of limk-1, its analogues and ligands for the production of a medicament against a thrombus formation or blood clotting disease |
| 06/16/2005 | WO2005053733A1 Botulinum toxin treatment of spastic bladder |
| 06/16/2005 | WO2005053732A1 Biomarkers for the efficacy of somatostatin analogue treatment |
| 06/16/2005 | WO2005053731A1 Biomarkers for the efficacy of calcitonin and parathyroid hormone treatment |
| 06/16/2005 | WO2005053730A1 Therapeutic agent for terminal heart failure |
| 06/16/2005 | WO2005053729A1 Stem cell factor for inducing neural stem cell migration to areas of neurological injury |
| 06/16/2005 | WO2005053728A2 Obesity-associated proteins and the use thereof in therapy and diagnosis |
| 06/16/2005 | WO2005053727A2 Pharmaceutical compositions for bioactive peptide agents |
| 06/16/2005 | WO2005053726A1 Selective neuropeptide y2 receptor agonists |
| 06/16/2005 | WO2005053725A2 Cancer treatment |
| 06/16/2005 | WO2005053667A1 Novel use of peptide compounds for treating central neuropathic pain |
| 06/16/2005 | WO2005053665A1 Treating infectious diseases using ice inhibitors |
| 06/16/2005 | WO2005053662A1 Dna damage repair inhibitors for treatment of cancer |
| 06/16/2005 | WO2005053642A1 Drug delivery vehicles and uses thereof |
| 06/16/2005 | WO2005053618A2 Synthetic hla binding peptide analogues and uses thereof |
| 06/16/2005 | WO2005053617A2 Compositions and methods comprising collagen |
| 06/16/2005 | WO2005041877A3 Method of inhibiting rejection following organ transplantation |
| 06/16/2005 | WO2005039642B1 Dna delivery with gemini cationic surfactants |
| 06/16/2005 | WO2005039626A3 Use of hydroxylated amino acids for treating diabetes |
| 06/16/2005 | WO2005039622A3 Modulation of socs expression in the therapeutic regimens |
| 06/16/2005 | WO2005034989A3 Use of somatostatin or one of the analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve in non-menopausal women |
| 06/16/2005 | WO2005029035A3 Methods of screening compositions for g protein-coupled receptor agonist activity |
| 06/16/2005 | WO2005029034A3 Methods for the identification of inhibitors of amidophosphoribosyltransferase and cutinase transcription factor 1 as antibiotics |
| 06/16/2005 | WO2005027953A3 Use of proline specific endoproteases to hydrolyse peptides and proteins |
| 06/16/2005 | WO2005027850A3 Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| 06/16/2005 | WO2005023862A3 Homogeneous preparations of il-28 and il-29 |
| 06/16/2005 | WO2005023861A3 Gdnf-related neuropeptides |
| 06/16/2005 | WO2005020962A8 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 06/16/2005 | WO2005018650A3 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent |
| 06/16/2005 | WO2005014029A3 Use of dg008, dg065, dg210 or dg 239 secreted protein products for preventing and treating pancreatic diseases, obesity or metabolic syndrome |
| 06/16/2005 | WO2005013899A9 Compositions and methods for the therapy and diagnosis of lung cancer |
| 06/16/2005 | WO2005000878A3 Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
| 06/16/2005 | WO2004111192A3 Targeted delivery to legumain-expressing cells |
| 06/16/2005 | WO2004104193A3 Phospholipase c |
| 06/16/2005 | WO2004101742A3 Protease inhibitors for coronaviruses and sars-cov and the use thereof |
| 06/16/2005 | WO2004099782A3 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39) |
| 06/16/2005 | WO2004098536A3 Anti-viral activity of cathelicidin peptides |
| 06/16/2005 | WO2004094471A3 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| 06/16/2005 | WO2004084825A3 Wound healing composition derived from low platelet concentration plasma |
| 06/16/2005 | WO2004078779A3 Conopeptides and methods of use |
| 06/16/2005 | WO2004067028A8 Compound for attenuating reaction of recipient tissues to an exogenic material and method for preparing an implant/transplant for contacting tissues of the organism of said recipient |
| 06/16/2005 | WO2004060280A3 Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
| 06/16/2005 | WO2004052305A3 Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |